Press release
Phosphoinositide 3-Kinase Inhibitor Pipeline Analysis, 2016 by P&S Market Research
Explore Report at: www.psmarketresearch.com/market-analysis/phosphoinositide-3-kinase-inhibitor-pipeline-analysis
The PI3K inhibitor pipeline has more than 45 drugs. In pipeline analysis, drugs are analyzed on the basis of route of administration and molecule type. The pipeline is also analyzed on the basis of monotherapy and combination therapy, and different clinical phases including Phase III, Phase II, Phase I and Pre-clinical stage.
Phase III & Filed
Phase III clinical trial known for the comparison of new treatments with the standard treatment in which safety, efficacy and side effects of new intervention is compared with the already existing treatment. The Phase III clinical trial takes around 2-3 years to complete and the total number of participants vary from 100-1,000. After the completion of Phase III stage, the company files New Drug Application to the regulatory authorities known as filed stage. Currently, there are 7 PI3K inhibitor drug candidates in Phase III clinical trial. Novartis AG has developed Alpelisib, an oral drug candidate for the treatment of hormone receptor-positive and hormone receptor-negative advanced breast cancer (postmenopausal women) as 2nd line therapy.
Phase II
LY-3023414, a drug candidate under development by Eli Lilly and Company is in Phase II stage of development for the treatment of endometrial cancer, non-small cell lung cancer and prostate cancer. Phase II clinical trial is the second Phase that answer safety, efficacy and dosing of the new intervention. There are total 9 PI3K inhibitor drugs present in phase II clinical trial. Phase II clinical trial take around 2 years to complete and between 100 – 120 patients participate in the Phase II trial.
Phase I
AZD-8186 is a PI3K beta and delta inhibitor under development by AstraZeneca. The drug candidate is in Phase I stage of development for the treatment of advanced castrate-resistant prostate cancer, squamous non-small cell lung cancer and triple negative breast cancer. There are 10 drugs present in Phase I clinical stage. In Phase I clinical trial, safety of the new intervention is determined. The trial takes around 1-2 years to complete and the total number of volunteers participating in the trial vary between 15 – 30.
Request for Table of Content at: www.psmarketresearch.com/market-analysis/phosphoinositide-3-kinase-inhibitor-pipeline-analysis/toc-sample
Pre-Clinical
SRX 2523 is based on control resulting from inhibiting multiple pathways platform technology. It is a pre-clinical drug candidate of SignalRX Pharmaceuticals, Inc. It is being developed for the treatment of chronic lymphocytic leukemia, multiple myeloma, medulloblastoma and neuroblastoma. There are 11 drugs present in pre-clinical stage. Pre-clinical study is also known as animal study. It is done before testing a drug in people to find out the toxicity profile of the drug. Pre-clinical study is of two types, including In vitro and In vivo.
Browse Other Related Report at: www.psmarketresearch.com/industry-report/pharmaceuticals
Pipeline analysis provides description about the key companies developing PI3K inhibitor drugs. Some of the key players actively involved in the research and development are GlaxoSmithKline plc, Pfizer, Inc., Novartis AG, SignalRX Pharmaceuticals, Inc., Eli Lilly & Company, Incyte Corporation, Amgen, Inc., and AstraZeneca plc.
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.
As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.
Contact:
Abhishek
Executive – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: www.psmarketresearch.com
347, 5th Ave. #1402
New York City, NY - 10016
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Phosphoinositide 3-Kinase Inhibitor Pipeline Analysis, 2016 by P&S Market Research here
News-ID: 465364 • Views: …
More Releases from P&S Market Research- Pharmaceuticals
Benign Prostatic Hyperplasia Therapeutics Market - Epidemiology Analysis, Therap …
The global benign prostatic hyperplasia therapeutics market is expected to witness significant growth, as increased number of effective treatments are available for cancer. Increasing awareness regarding various cancer treatment drugs, technological advancements, and growing demand for safe and effective medications are acting as the major growth drivers for the benign prostatic hyperplasia therapeutics market. Globally, regulatory bodies are adding to the growth of the market with provision of funding, grants…
Global Esophageal Cancer Therapeutics Market Analysis, Development and Demand Fo …
Global esophageal cancer therapeutics market is expected to witness significant growth with an increasing awareness regarding cancer treatment and technological advancements. Also, high demand for safe and effective medications and rising prevalence of cancer are driving the growth of the global market. The regulatory bodies such as USFDA, EMA are supporting the growth of the global market by providing funding, designations and grants for speeding up the drug development process.
Explore…
Pancreatic Cancer Therapeutics Market - Epidemiology Analysis, Therapy, Developm …
The global pancreatic cancer therapeutics market holds numerous opportunities for the key players, as pancreatic cancer is a highly challenging disease among all types of cancer, which has no specific treatment available for it, as of now. Also, growing incidence of cancer and technological advancements are supporting the growth of the global pancreatic cancer therapeutics market growth.
Explore Report at: www.psmarketresearch.com/market-analysis/pancreatic-cancer-therapeutics-market
Cancer instigates uncountable growth of cells due to some abnormalities…
Novel Targets for Breast Cancer Treatment Drive Estrogen Receptor-Positive (ER+) …
Estrogen Receptor-Positive (ER+) breast cancer currently exhibits a pipeline with 46 active drug candidates.
ER+ breast cancer pipeline offers novel therapeutic targets for the treatment of breast cancer
The study analyzed that the estrogen receptor positive breast cancer pipeline comprises approximately 74 drug candidates, of which nine products are in Phase III, 16 products in Phase II, 18 products in Phase I, and three products are in Pre-Clinical stage. The development of…
More Releases for Phase
PanAfGeo: The Second Phase Begins!
The PanAfGeo community is pleased to announce the launching of the PanAfGeo second phase (PanAfGeo-2), which will continue to build on the first phase project’s achievements over the next three years.
PanAfGeo, an EU co-funded initiative that began in 2016, contributed to the transfer of knowledge between European and African Geological Surveys. PanAfGeo also ensured the institutional strengthening of many African national administrations in charge of geology and mining.
With the backing…
COVID-19 - Pipeline Analysis 2020 for Global Market | Emphasis on Products cover …
COVID-19 (also known as Anderson COVID-19)?is a viral disease caused by RNA virus, SARS-CoV-2 or commonly known as corona virus. These viruses can cause respiratory, enteric, hepatic, and neurologic diseases. At the end of 2019, a new coronavirus was identified as the cause of a cluster of pneumonia cases in Wuhan, China. It rapidly spread, resulting in an epidemic throughout China, followed by an increasing number of cases in other…
Power Metering Market Information by type (smart, digital, analog), by phase (si …
Power Metering Market Information by type (smart, digital, analog), by phase (single phase, three phase) by application (residential, commercial and industrial) and Region - Forecast to 2022
The report for Global Power Metering Market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and…
HIV Vaccines Market Perceive Aggrandized Growth at a CAGR of 11.48% Till 2023 | …
HIV Vaccines Market Report Added on MarketResearchFuture.com with Overall Analysis. Key developments and Strategies Cover in this Report. The Market for Expected to Grow Globally Over the CAGR of 5 % During the Period 2018 to 2027 from USD 2,702.3 Billion in 2027.
HIV Vaccines Market - Segmentation
The global HIV vaccines market has been segmented on the basis of basis of antibiotics, type, and lastly, region.
Antibiotics have been segmented into dicloxacillin,…
2026 Global Pharmacovigilance Market Growth Analysis by Clinical Trials Like Pre …
Global Pharmacovigilance Market 2018 report includes extensive Market analysis and industry landscape along with SWOT analysis and PESTEL analysis of the important vendors. The analysis is conducted with a blend of secondary and primary advice for inputs from participants in the industry. Pharmacovigilance industry report covers the prospects of Women’S Health P oducts in the forecast period of 2018-2026 and the scenario.
Growing prevalence of adverse reactions caused by drugs, has…
MAAT Inaugurates Versatile Phase Shifter
Company announces release of a digital recreation of Roger Schult’s analog hardware
MAAT Incorporated, a manufacturer of exceptional performance professional audio solutions, today announced the release of RSPhaseShifter version 1.0, a digital implementation of the Roger Schult/German Audio Lab’s Phase Shifter 500 Series W2324 hardware. The cross–platform plug–in creates a high quality, phase shifted version of a monaural or stereo input.
Available in formats for all major DAWs (Digital Audio Workstations), RSPhaseShifter…
